StockData

HCW Biologics vs Zenas BioPharma

HCWB and ZBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HCWB and ZBIO compare

Zenas BioPharma is the larger company, worth 1268 times as much as HCW Biologics ($1.8B against $1.4M).

HCW Biologics scores higher on the StockData Score (6 against 1 for Zenas BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHCWBZBIO
Size and price
Market cap$1.4M$1.8B
Share price$0.777$27.75
Change, 1 year−95.7%−20.7%
Change, 5 years−99.9%–
Beta (5Y)2.480.25
Employees–167
StockData Score
Total score6 (better)1
Valuation score3 (better)0
Growth score2 (better)0
Performance score1 (better)0
Health score01 (better)
Dividend score00
Valuation
P/S0.2×–
P/B0.2× (better)8.5×
FCF yield–−13.4%
Fair value$15.10–
Margin of safety94.9%–
Growth
Revenue growth (TTM)700%–
Revenue growth, 5Y average−57.9%–
Profitability
Gross margin96.7%–
Operating margin−115%–
Net margin−83.8%–
Return on equity−151% (better)−265%
Return on invested capital−70.7%–
Financial health
Debt / equity0.88 (better)1.05
Interest coverage−14.0×–
Current ratio0.069.42 (better)
Altman Z-score−7.21−1.48 (better)
Piotroski F-score2 (better)1
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions5.6%94.0%
Held by insiders34.9%36.1%
Insider net buying, 12 months$532K$11.4M (better)
Short interest, % of float4.1%27.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.